Two Sigma Investments LP Reduces Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Two Sigma Investments LP reduced its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 15.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 423,774 shares of the company's stock after selling 74,816 shares during the period. Two Sigma Investments LP owned about 0.49% of IDEAYA Biosciences worth $10,891,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Rhumbline Advisers lifted its stake in shares of IDEAYA Biosciences by 0.5% during the 4th quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after acquiring an additional 585 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in IDEAYA Biosciences by 44.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after purchasing an additional 853 shares during the period. Mariner LLC increased its holdings in IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares during the period. Assetmark Inc. increased its holdings in IDEAYA Biosciences by 2.5% during the 4th quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after purchasing an additional 1,084 shares during the period. Finally, R Squared Ltd purchased a new position in IDEAYA Biosciences during the 4th quarter worth $35,000. 98.29% of the stock is owned by institutional investors.

Analyst Ratings Changes

IDYA has been the topic of several research reports. Stephens restated an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a report on Friday, February 14th. JPMorgan Chase & Co. raised their price objective on IDEAYA Biosciences from $63.00 to $66.00 and gave the stock an "overweight" rating in a report on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Trading Up 2.4%

Shares of NASDAQ:IDYA traded up $0.47 on Thursday, reaching $20.03. The company had a trading volume of 502,444 shares, compared to its average volume of 1,002,419. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $44.42. The firm's 50 day simple moving average is $17.71 and its 200-day simple moving average is $21.68. The firm has a market capitalization of $1.75 billion, a PE ratio of -6.06 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the firm posted ($0.53) earnings per share. As a group, equities research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.